Low expression of BMPRIB indicates poor prognosis of breast cancer and is insensitive to taxane-anthracycline chemotherapy.

Dai, Kun

Low expression of BMPRIB indicates poor prognosis of breast cancer and is insensitive to taxane-anthracycline chemotherapy. [electronic resource] - Oncotarget Jan 2016 - 4770-84 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

1949-2553

10.18632/oncotarget.6613 doi


Adult
Aged
Aged, 80 and over
Anthracyclines--administration & dosage
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Biomarkers, Tumor--metabolism
Bone Morphogenetic Protein Receptors, Type I--metabolism
Breast Neoplasms--drug therapy
Bridged-Ring Compounds--administration & dosage
Carcinoma, Ductal, Breast--drug therapy
Female
Follow-Up Studies
Humans
Immunoenzyme Techniques
Lymphatic Metastasis
Middle Aged
Neoadjuvant Therapy
Neoplasm Grading
Neoplasm Invasiveness
Neoplasm Staging
Prognosis
Receptor, ErbB-2--metabolism
Receptors, Estrogen--metabolism
Receptors, Progesterone--metabolism
Retrospective Studies
Survival Rate
Taxoids--administration & dosage